Compare · CRL vs LUNA
CRL vs LUNA
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and Luna Innovations Incorporated (LUNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and LUNA operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $11.31B, about 52.2x LUNA ($216.7M).
- Over the past year, CRL is up 33.2% and LUNA is up 0.0% - CRL leads by 33.2 points.
- CRL has hit the wire 3 times in the past 4 weeks while LUNA has been quiet.
- CRL has more recent analyst coverage (25 ratings vs 4 for LUNA).
- Company
- Charles River Laboratories International Inc.
- Luna Innovations Incorporated
- Price
- $234.83-2.27%
- $0.88-57.07%
- Market cap
- $11.31B
- $216.7M
- 1M return
- +4.15%
- +0.00%
- 1Y return
- +33.23%
- +0.00%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- 2006
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 4
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Luna Innovations Incorporated
Luna Innovations Incorporated develops, manufactures, and markets fiber optic test, measurement, and control products worldwide. It operates through two segments, Lightwave and Luna Labs. The Lightwave segment offers test and measurement products, which include optical vector analyzer, optical backscatter reflectometers, and the Phoenix family of tunable lasers; and Hyperion sensing solution that enable full-spectrum data acquisition and flexible peak detect algorithms of fiber-bragg grating (FBG), long period FBGs and fabry-perot sensors with low-latency access to data for closed loop feedback applications. This segment also provides polarization control products, including components, modules, and instruments to measure, manage, and control polarization and group delay in fiber optic networks; tunable lasers; Terametrix terahertz gauging and imaging products that provides precise single and multi-layer thickness, density, basis weight, and caliper thickness measurements; ODiSI sensing solution, which provides distributed strain and temperature measurements; and Hyperion sensing products that targets fiber optic sensing applications. The Luna Labs segment provides applied research for customers principally in the areas of sensing and materials, such as coatings, adhesives, composites, and bio-engineered materials. The company sells its products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was incorporated in 1990 and is headquartered in Roanoke, Virginia.
Latest CRL
- Charles River downgraded by CLSA with a new price target
- Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
- Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
- Director Foster James C sold $16,875,000 worth of shares (75,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 31,596 units (SEC Form 4)
- Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
- Charles River upgraded by Morgan Stanley with a new price target
- Director Foster James C gifted 183,361 shares and received a gift of 183,361 shares, decreasing direct ownership by 62% to 106,596 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit gifted 3,386 shares and received a gift of 3,386 shares, decreasing direct ownership by 9% to 36,013 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M gifted 1,529 shares and received a gift of 1,529 shares, decreasing direct ownership by 13% to 9,853 units (SEC Form 4)
- Director Barg Steven was granted 422 shares, increasing direct ownership by 15% to 3,287 units (SEC Form 4)
Latest LUNA
- Luna Innovations Enters into Definitive Agreement to be Acquired by TJC
- Luna Innovations Incorporated - Notice of Pendency and Proposed Settlement of Stockholder Derivative Action
- Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion
- Luna Announces Strong Start to 2025 with Substantial Bookings Growth
- Luna Innovations Announces Baker Tilly as New Independent Auditor
- Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Luna Announces Updates on Operating Metrics and Intent to Deregister Stock
- SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated
- Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Luna Innovations Stock to Be Suspended from Nasdaq Listing